Technology area: Biotechnology & Pharmaceuticals
18 pending office actions • 16 art units • 18 examiners • 0 of 18 (0%) have an AI response strategy ready • 23 patents granted in the last 365 days
United States Department of the Army has 20 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 20 examiners and 18 art units, indicating broad examiner distribution with modest concentration among technical groups. The profile does not support relying on one examiner-specific approach across the docket.
ROZANSKI, MICHAEL T is the busiest identified examiner, with 1 pending matter. Counsel should prioritize centralized tracking of claim support and disclosure while tailoring each response to its assigned examiner and art unit.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (11%) |
| §103 only | 2 (11%) |
| §112 only | 2 (11%) |
| Double-patenting + other | 2 (11%) |
| Multi-statute (no §101) | 10 (56%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROZANSKI, MICHAEL T | 1 | 69.1% | +29.0% |
| SMITH, PETER DANIEL | 1 | 51.3% | +48.8% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| MOORE, JOHN DAVID | 1 | 61.1% | +28.3% |
| LEE, CHIHYI NMN | 1 | 33.3% | +61.1% |
| CHESTNUT, BARRY A | 1 | 73.9% | +6.3% |
| OMETZ, DAVID LOUIS | 1 | 76.2% | -8.8% |
| ALLEN, ROBERT F | 1 | 72.9% | +62.6% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| PRONZATI, GINA | 1 | 65.9% | +48.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18805212 | PROLYL HYDROXYLASE DOMAIN INHIBITOR FOR TREATING HEMORRHAGIC OR BURN SHOCK | INAM, SAHAR | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18379740 | PROLYL HYDROXYLASE DOMAIN INHIBITOR TREATMENT TO IMPROVE SURVIVABILITY OF HEMORRHAGIC SHOCK | PRONZATI, GINA | 23d overdue |
| 18173551 | BIOMARKERS OF IMMUNE DYSFUNCTION IN RESPONSE TO CHRONIC STRESS, METHODS OF USE AND DIAGNOSTIC KITS | FLINDERS, JEREMY C | 16d overdue |
| 19121238 | BODY COMPOSITION PREDICTION BY THE SUMMATION OF REGIONAL ESTIMATES DETERMINED FROM ANATOMICAL SUBREGION GEOMETRY | ROZANSKI, MICHAEL T | — |
| 18854087 | Ocular Chemical Injury Treatment Ring and Method of Use | SMITH, PETER DANIEL | — |
| 18800672 | NOVEL RAPID DRUG DISCOVERY FOR SEPSIS AND AGENTS FOR USE AS SEPSIS THERAPY | MOORE, JOHN DAVID | — |
| 18794153 | Methods for Treating Traumatic Brain Injury | LEE, CHIHYI NMN | — |
| 18744397 | Method of Generating Phage Clones with Expanded Activity | CHESTNUT, BARRY A | — |
| 18628287 | Adaptive Closed Loop Hemorrhagic Shock Resuscitation Controller | ALLEN, ROBERT F | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18379740 | PROLYL HYDROXYLASE DOMAIN INHIBITOR TREATMENT TO IMPROVE SURVIVABILITY OF HEMORRHAGIC SHOCK | PRONZATI, GINA | 23d overdue |
| 19121238 | BODY COMPOSITION PREDICTION BY THE SUMMATION OF REGIONAL ESTIMATES DETERMINED FROM ANATOMICAL SUBREGION GEOMETRY | ROZANSKI, MICHAEL T | — |
| 18854087 | Ocular Chemical Injury Treatment Ring and Method of Use | SMITH, PETER DANIEL | — |
| 18800672 | NOVEL RAPID DRUG DISCOVERY FOR SEPSIS AND AGENTS FOR USE AS SEPSIS THERAPY | MOORE, JOHN DAVID | — |
| 18794153 | Methods for Treating Traumatic Brain Injury | LEE, CHIHYI NMN | — |
| 18628287 | Adaptive Closed Loop Hemorrhagic Shock Resuscitation Controller | ALLEN, ROBERT F | — |
| Art Unit | Apps |
|---|---|
| 1672 | 3 |
| 3797 | 1 |
| 3781 | 1 |
| 1622 | 1 |
| 1638 | 1 |
| 1628 | 1 |
| 2672 | 1 |
| 3783 | 1 |
| 1633 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19121238 | BODY COMPOSITION PREDICTION BY THE SUMMATION OF REGIONAL ESTIMATES DETERMINED FROM ANATOMICAL SUBREGION GEOMETRY | ROZANSKI, MICHAEL T | 3797 | §102§103§112 | Non-Final OA | — | Pending | Apr 15, 2025 |
| 18854087 | Ocular Chemical Injury Treatment Ring and Method of Use | SMITH, PETER DANIEL | 3781 | §102§103 | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18805212 | PROLYL HYDROXYLASE DOMAIN INHIBITOR FOR TREATING HEMORRHAGIC OR BURN SHOCK | INAM, SAHAR | 1622 | §103§112DP | Non-Final OA | — | Pending | Aug 14, 2024 |
| 18800672 | NOVEL RAPID DRUG DISCOVERY FOR SEPSIS AND AGENTS FOR USE AS SEPSIS THERAPY | MOORE, JOHN DAVID | 1638 | §103§112 | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18794153 | Methods for Treating Traumatic Brain Injury | LEE, CHIHYI NMN | 1628 | §103§112 | Non-Final OA | — | Pending | Aug 05, 2024 |
| 18744397 | Method of Generating Phage Clones with Expanded Activity | CHESTNUT, BARRY A | 1672 | §102§112 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18671239 | Transform Upon Image Area of Interest | OMETZ, DAVID LOUIS | 2672 | §103 | Non-Final OA | — | Pending | May 22, 2024 |
| 18628287 | Adaptive Closed Loop Hemorrhagic Shock Resuscitation Controller | ALLEN, ROBERT F | 3783 | §103§112 | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18685041 | IgA MONOCLONAL ANTIBODIES FOR TREATING FLAVIVIRUS INFECTION | ALAM, DANYAL HASSAN | 1672 | §112 | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18379740 | PROLYL HYDROXYLASE DOMAIN INHIBITOR TREATMENT TO IMPROVE SURVIVABILITY OF HEMORRHAGIC SHOCK | PRONZATI, GINA | 1633 | §102§103§112Other | Non-Final OA | 23d overdue | Pending | Oct 13, 2023 |
| 18173551 | BIOMARKERS OF IMMUNE DYSFUNCTION IN RESPONSE TO CHRONIC STRESS, METHODS OF USE AND DIAGNOSTIC KITS | FLINDERS, JEREMY C | 1684 | §102§112Other | Non-Final OA | 16d overdue | Pending | Feb 23, 2023 |
| 17905614 | VACCINES AGAINST SARS-COV-2 AND OTHER CORONAVIRUSES | BUCKMASTER, MARLENE VRENI | 1672 | §102§103§112DP | Final Rejection | 114d overdue | Pending | Sep 02, 2022 |
| 17829164 | ANTI-CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USE | LU, CHENG | 1642 | §101§112Other | Non-Final OA | — | Pending | May 31, 2022 |
| 18896918 | END-TO-END CONNECTION FOR LIGHTWEIGHT AIRFIELD MATTING SYSTEM | LEE, JONG SUK | 2875 | §102§103 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18896915 | LIGHTWEIGHT AIRFIELD MATTING SYSTEM | HARTMANN, GARY S | 3671 | §102§103§112 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18375410 | ADVANCED THIOL-ENE COMPOSITES THAT UNDERGO RADIOFREQUENCY INDUCED ACTUATION | PATEL, RONAK C | 1788 | §103 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18372133 | SYSTEM AND METHOD FOR DETERMINING ESTIMATED ANNUAL PAVEMENT COST | NGUYEN, NGA B | 3625 | §101§112 | Final Rejection | — | Pending | Sep 25, 2023 |
| 17503258 | AMINE FUNCTIONALIZED CHITIN FOR REMOVING MUNITIONS COMPOUNDS FROM SOLUTION | CRAIGO, BAHAR ALAWI | 1699 | §112 | Final Rejection | — | Pending | Oct 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUnited States Department of the Army has 18 pending office actions as of October 2026, spread across 16 art units and 18 examiners.
Michael T Rozanski has the most, with 1 of United States Department of the Army's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
